OCA
PVLA

Octagon Capital Advisors’s Palvella Therapeutics PVLA Stock Holding History

Octagon Capital Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-82,500
Closed -$1.09M – 48
2023
Q2 		$1.09M Buy
82,500
+78,731
+2,089% +$4.77M 0.15% 38
2023
Q1 		$294K Buy
+3,769
New +$436K 0.04% 36

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Octagon Capital Advisors's PVLA Position: Q3 2023 in Review

Octagon Capital Advisors sold out of Palvella Therapeutics (PVLA) in Q3 2023, closing a stake of 82,500 shares — an estimated $1.09M sold.

Octagon Capital Advisors first reported a position in PVLA in Q1 2023 and held it in 2 quarters. The position peaked at $1.09M in Q2 2023. 43 funds tracked by Wall St. Rank hold PVLA as of Q3 2023.

  • Octagon Capital Advisors reported no remaining Palvella Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 82,500 Palvella Therapeutics shares in Q3 2023, an estimated $1.09M.
  • Octagon Capital Advisors first reported a position in Palvella Therapeutics in Q1 2023 and held it in 2 quarters.
  • Octagon Capital Advisors's Palvella Therapeutics position peaked at $1.09M in Q2 2023.
  • 43 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2023.

Based on Octagon Capital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.